Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 14, 2012

View Archived Issues

NanoCarrier and LFB Biotechnologies refocus research collaboration

Anergis reports long-term immunomodulation with AllerT vaccine

STOP-ALF study of OCR-002 begins

Preliminary clinical results presented for FG-4592 in hemodialysis patients

sGPVI as a risk marker in inflammatory arthritis

Edison Pharmaceuticals commences phase IIb trial of EPI-743 in children with Leigh syndrome

Kyowa Hakko Kirin files new application for KW-2246 in Japan

Aeterna Zentaris' phase I/II study of AEZS-108 advances

Novel dual NADPH oxidase inhibitor shows excellent safety/pharmacokinetic profile

NDA for nonhormonal therapy for menopausal vasomotor symptoms accepted for review by FDA

Vaccibody receives grant to develop therapeutic cervical cancer vaccine

Foundation Medicine develops genomic profiling collaborations

Phase I results presented for the FMP-012 malaria vaccine

Roche launches Elecsys HE4 assay in U.S.

MRC reports results of heterologus prime vaccination study at the ASTMH meeting in Atlanta

Teknologian Tutkimuskeskus patents new pollen allergen polypeptides

Novel enhancers of SMN2 expression presented by AMRI and HHS

AstraZeneca presents novel PI3K inhibitors

Allon Therapeutics completes treatment in pivotal davunetide trial

Researchers divulge new SERMs for the treatment of breast cancer

Sunshine Biopharma begins IND-enabling studies for Adva-27a

Otsuka Pharmaceutical patents new antibacterial agents

Nuron Biotech completes enrollment in pivotal NU-100 trial

Novartis discloses novel prodrugs of SGLT1/2 inhibitors

Tiltan Pharma enrolls first U.S. patient in phase II TL-118 study

Joint effort between Eisai and Epizyme results in new EZH2 inhibitors

Colby and MannKind sign agreement to develop cancer immunotherapy products